A 72-year-old male with a recent diagnosis of acute myeloid leukemia (AML) had been commenced on chemotherapydaunorubicin and cytarabine. He was also on ciprofloxacin, posaconazole and acyclovir for antimicrobial prophylaxis.
A number of neutrophilic dermatoses are associated with malignancies and their treatment. These rarely occur together in the same patient.
A Caucasian 72-year-old male was treated for acute myeloid leukemia (AML) with chemotherapy including daunorubicin and cytarabine. Within 48 hours of commencing treatment, he developed pyrexia and, two days later, disseminated non-tender pink plaques on the limbs and trunk. A skin biopsy showed a dermal interstitial infiltrate of lymphocytes, histiocytoid cells and predominantly neutrophils. This extended into the subcutis, where a neutrophilic lobular panniculitis was seen. These findings are consistent with Sweet's syndrome. In addition, a neutrophilic and lymphocytic infiltrate was also present around eccrine coils and lower ducts. The eccrine epithelium showed squamous metaplasia with dyskeratosis and sloughing into the lumen. These latter findings are consistent with neutrophilic eccrine hidradenitis (NEH).
These two histologically distinct entities form part of the neutrophilic dermatoses that have been described in oncology patients with reports of concurrent or sequential occurrence of various neutrophilic dermatoses in the same patient. Ours, however, is only the second reported case of simultaneously captured Sweet's and NEH in the setting of AML. The most likely explanation is that of an epiphenomenon, whereby the neutrophilic infiltrate extended around the sweat glands in the context of the neutrophilic dermatosis. 
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of pathological changes described has expanded. There can be variability in the composition of the infiltrate as well as its depth. We could hypothesize that this case describes yet a further expansion of the pathological description. However, the occurrence of these two entities concurrently, in this same patient, is not entirely unexpected. The patient had a hematological malignancy well known to be associated with Sweet's syndrome and at the same time was receiving an agent, cytarabine, that has a well-established association with NEH. Thus we feel the most likely explanation is that of an epiphenomenon, where by the neutrophilic infiltrate has extended around the sweat glands in the context of the neutrophilic dermatosis.
A few lymphocytes are typically present in older lesions, in a perivascular pattern. Vasculitis is usually absent [3] , although a secondary leukocytoclastic vasculitis has been described in several cases [2] .
NEH is a more recently characterized entity-first reported in a patient treated with cytarabine for AML [4] .
Since then, other malignancies and chemotherapeutic agents have been implicated. The histological hallmark is a neutrophilic infiltrate around and within eccrine secretory coils often associated with vacuolar degeneration and even necrosis of the secretory epithelium. The NEH literature does not report any neutrophilic infiltrates away from the eccrine sweat glands. In the setting of neutropenia the infiltrate may be sparse [5] . Squamous metaplasia is occasionally seen.
The pathologic mechanism of NEH remains unclear. It was postulated to be linked to the high concentrations of chemotherapy drugs secreted into eccrine glands, however cases of NEH have been seen in the absence of chemotherapy and AML [6] .
These two histologically distinct entities form part of the neutrophilic dermatoses that have been described in oncology patients. There are reports of concurrent or sequential occurrence of various neutrophilic dermatoses in the same patient [7] . However, ours is the second reported case of simultaneous Sweet-like neutrophilic dermatosis and NEH.
There is a case similar to ours where there was a background of AML treated with chemotherapy, including cytarabine, in a patient with both Sweet's and NEH. The patient suffered a recurrence of the eruption when a relapse of the AML was treated with chemotherapy, but did not have a recurrence when consolidation chemotherapy was given during remission [8] . Our patient did have a recurrence of AML 8 weeks after completing his second cycle of chemotherapy. Since then he has been on azacitidine (an antimetabolite) to control disease progression. To date he has not experienced a recurrence of the cutaneous eruption. Another case of concomitant Sweet's plus NEH reported in the Tunisian literature appeared to be idiopathic [9] .
Conclusion
Since Sweet's syndrome was initially recognized, the spectrum
